The Intensive Care Bundle with Mortality Reduction in Acute Ischemic Stroke Trial
NCT06628817 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 55000
Last updated 2024-10-08
Summary
Ischemic stroke, also known as cerebral infarction, accounts for as high as 60% to 80% of all stroke cases, and it is characterized by high morbidity, high disability rate, and high mortality rate. In recent years, acute ischemic stroke (AIS) has risen to the top of the list of causes of death in Chinese people, bringing a heavy burden on families, society and the country. In the process of continuous accumulation of evidence-based evidence, the management of stroke has gradually become systematic, and the demand for multi-disciplinary collaboration has become increasingly prominent, thus the concept of organized medical care has emerged.
Improving the prognosis of stroke faces multiple challenges, including timely identification of stroke patients, intravenous thrombolysis after clinical doctors evaluate indications and contraindications, reducing in-hospital stroke complications, accurately diagnosing the cause of stroke and implementing precise prevention. In the past, there were relatively few clinical trials on reducing mortality. The 2023 Dutch PRECIOUS study used metoclopramide, ceftriaxone and acetaminophen to prevent aspiration, infection and fever in elderly patients with acute stroke. The results showed that there was no significant difference in acute 90-day good functional outcomes and reduced mortality. The INTERACT3 trial results showed that for patients with acute cerebral hemorrhage, compared with conventional medical care, the use of a new combination management plan, namely early intensive blood pressure management, strict control of blood sugar elevation, body temperature control and anticoagulation therapy, can significantly reduce the risk of 6-month adverse functional prognosis in patients, improve the survival rate and quality of life of patients, and the possibility of patients being discharged within 7 days. Therefore, the use of a new combination management plan, including improving the efficiency of reperfusion therapy, reducing the occurrence of stroke complications, and carrying out precise etiological treatment, may reduce the mortality rate of patients.
The Zhejiang Stroke Online Platform can monitor the comprehensive information of treatment and management in the process of clinical doctors receiving AIS patients in real time. According to the self-feedback of each unit of the online platform, the provincial center conducts multi-level new combined management intervention on it. The purpose of this study is to explore whether the new combined management intervention measures can reduce the mortality rate of AIS patients on the basis of the implementation of stroke online platform monitoring.
Conditions
- Acute Ischemic Stroke
Interventions
- RADIATION
-
The Intensive Care Bundle with Mortality Reduction
a continuous automated medical quality monitoring and feedback system on the online platform, self-feedback and teamwork based on video conferencing, multidisciplinary online education, offline on-site supervision, and standardized intervention in the behavior of medical actors in the process of stroke treatment.
Sponsors & Collaborators
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- HEALTH_SERVICES_RESEARCH
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-01
- Primary Completion
- 2025-10-30
- Completion
- 2026-11-01
More Related Trials
-
Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy
NCT06629116 ·Status: RECRUITING ·Phase: NA
-
Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke
NCT06863571 ·Status: RECRUITING ·Phase: PHASE3
-
Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer
NCT06841965 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Reperfusion Therapy
NCT06538844 ·Status: COMPLETED ·Phase: PHASE2
-
The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion
NCT02594995 ·Status: COMPLETED ·Phase: PHASE4
-
INtravenous TNK for Acute isChemicsTroke in China
NCT04588337 ·Status: COMPLETED
-
Endovascular Therapy for Acute Ischemic Stroke Trial
NCT02350283 ·Status: COMPLETED ·Phase: PHASE3
-
CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase
NCT04086147 ·Status: COMPLETED ·Phase: PHASE2
-
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
NCT06058130 ·Status: RECRUITING ·Phase: NA
-
Efficacy and Safety of Tenecteplase Intravenous Thrombolysis in Acute Posterior Circulation Ischemic Stroke Within 4.5-24 Hours After Onset
NCT07094763 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308 ·Status: RECRUITING ·Phase: PHASE3
-
Normobaric Hyperoxia Combined With Reperfusion for Acute Ischemic Stroke
NCT03620370 ·Status: COMPLETED ·Phase: NA
-
Temporal Trends of Thrombolysis Treatment in Chinese Acute Ischemic Stroke (AIS) Patients From 2007-2017: Analysis of China National Stroke Registry (CNSR) I, II, and III; CTP-Draft Review Performed;
NCT04290494 ·Status: COMPLETED
-
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of TB006 in Participants With Acute Ischemic Stroke
NCT05156827 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke
NCT02152280 ·Status: UNKNOWN ·Phase: PHASE4
-
Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset
NCT02854592 ·Status: COMPLETED
-
Early Antiplatelet Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT)
NCT06548971 ·Status: RECRUITING ·Phase: PHASE3
-
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
NCT06010628 ·Status: RECRUITING ·Phase: PHASE4
-
Endovascular Thrombectomy With and Without Intravenous Thrombolysis in Extended Time Window
NCT05634382 ·Status: UNKNOWN ·Phase: PHASE3
-
Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China(IVTIS)
NCT06131385 ·Status: RECRUITING
-
Early Antiplatelet Therapy After Hemorrhagic Infarction in Acute Ischemic Stroke Treated With Intravenous Thrombolysis (HITs)
NCT04624295 ·Status: RECRUITING ·Phase: PHASE4
-
Efficacy and Safety of Human Urinary Kallidinogenase Combined With Endovascular Therapy in Acute Ischemic Stroke With Large Vessel Occlusion
NCT06211712 ·Status: RECRUITING ·Phase: NA
-
24 Hours Treatment with Alteplase in Patients with Ischemic Stroke
NCT04879615 ·Status: COMPLETED ·Phase: PHASE3
-
Intraarterial Stem Cells in Subacute Ischemic Stroke
NCT03080571 ·Status: COMPLETED ·Phase: PHASE1
-
Emergency Stroke Unit for Acute Cerebrovascular Events ( ESU-ACE-B )
NCT06492265 ·Status: RECRUITING ·Phase: PHASE2